what is known already: PCOS and MetS share many similarities, including abdominal obesity and IR, and PCOS is regarded as the ovarian manifestation of MetS. However, there are limited data on the differences between markers of IR and circulating androgens between women with these two syndromes. participants/materials, setting, methods: This study was performed in a university department of obstetrics and gynecology. The following markers of IR were determined: serum glucose and insulin levels, glucose/insulin ratio, area under the oral glucose tolerance test, homeostasis model assessment of IR index and quantitative insulin sensitivity check index.
Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by the presence of oligo-or anovulation, hyperandrogenemia and/or polycystic ovaries (Norman et al., 2007; Goodarzi et al., 2011) . A substantial proportion of women with PCOS also present with abdominal obesity and insulin resistance (IR) (Norman et al., 2007; Goodarzi et al., 2011) . In PCOS, IR appears to be mainly due to abdominal obesity, but it has been suggested that it also represents an intrinsic characteristic of this syndrome, independently of obesity (Norman et al., 2007; Goodarzi et al., 2011) .
Metabolic syndrome (MetS) represents a constellation of metabolic abnormalities, including abdominal obesity, impaired fasting glucose, dyslipidemia and hypertension (Cornier et al., 2008) . Abdominal obesity and IR appear to underpin the pathogenesis of MetS (Cornier et al., 2008) . Interestingly, accumulating data suggest that women with MetS are also characterized by elevated circulating androgens (Brand et al., 2011) . It is apparent that PCOS and MetS share many similarities and PCOS has been termed the 'ovarian' manifestation of MetS (Garruti et al., 2009; Kandaraki et al., 2009) .
Limited data suggest that women with both PCOS and MetS have more severe IR and more pronounced hyperandrogenemia than those with PCOS but without MetS (Apridonidze et al., 2005; Attaoua et al., 2008; Cussons et al., 2008; Cheang et al., 2009) . On the other hand, it is unclear whether women with PCOS but without MetS differ in markers of IR compared with those with MetS but without PCOS. In a large cohort of women with PCOS and BMI-matched controls, we aimed to compare metabolic and endocrine characteristics in: (i) women with PCOS and MetS (PCOS+ MetS+) and those with PCOS but without MetS (PCOS+MetS2) and (ii) women with PCOS but without MetS (PCOS+MetS2) and those with MetS but without PCOS (PCOS2MetS+).
Materials and Methods

Patients
We studied 1223 women with PCOS [mean + SD: age 24.7 + 5.8 years, BMI 27.5 + 6.9 kg/m 2 ] and 277 BMI-matched healthy women (age 31.3 + 5.4 years, BMI 26.6 + 6.7 kg/m 2 ) with normal ovulatory cycles (28 + 2 days, blood progesterone levels .31.8 nmol/l at mid-luteal phase in two consecutive cycles), no signs of hyperandrogenism and normal sonographic appearance of the ovaries (controls). All women with PCOS were outpatients at the Gynecological Endocrinology Infirmary of the Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki. Women in the control group were healthy volunteers. Diagnosis of PCOS was based on the revised Rotterdam criteria, which require the presence of at least two of the following three features: (i) oligo-or anovulation (,8 spontaneous hemorrhagic episodes/year), (ii) biochemical hyperandrogenemia (defined in our population as early follicular phase testosterone . 2.1 nmol/l, corresponding to the mean + 2 SD of 200 control subjects measured in our laboratory) or clinical manifestations of hyperandrogenemia and (iii) polycystic ovaries on ultrasound (≥12 small follicles in at least one ovary and/or ovarian volume .10 cm 3 ) (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) . Because it has been argued that the revised Rotterdam criteria are not stringent and that PCOS should be first considered a disorder of androgen excess or hyperandrogenism, we also performed additional analyses using the diagnostic criteria for PCOS proposed by the Androgen Excess Society (AES) . According to the AES criteria, the diagnosis of PCOS requires the presence of hyperandrogenism (hirsutism and/or hyperandrogenemia) and ovarian dysfunction (oligo-anovulation and/or polycystic ovaries) and the exclusion of other androgen excess or related disorders . Diagnosis of MetS was based on the definition recently proposed by the International Diabetes Federation (IDF), National Heart, Lung and Blood Institute (NHLBI), American Heart Association (AHA), World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity, which requires the presence of at least three of the following features: (i) abdominal obesity [waist circumference (WC) ≥80 cm], (ii) serum triglyceride (TG) levels ≥ 1.7 mmol/l, (iii) serum highdensity lipoprotein cholesterol (HDL-C) levels , 1.3 mmol/l, (iv) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥85 mmHg and (v) serum glucose levels ≥ 5.6 mmol/l (Alberti et al., 2009) .
None of the women studied had galactorrhea or any endocrine or systemic disease that could possibly affect reproductive physiology. An adrenocorticotrophic hormone test was performed with tetracosactide (Synachten 0.25 mg/1 ml; Novartis Pharma, Rueil-Malmaison, France) in women with a basal 17a-hydroxyprogesterone (17a-OHP) plasma level . 4.8 nmol/l to exclude congenital adrenal hyperplasia. No woman reported the use of any medication that could interfere with the normal function of the hypothalamic -pituitary -gonadal axis during the last 6 months.
Informed consent was obtained from all women, and the study was approved by the Institutional Review Board; the study met the requirements of the 1975 Helsinki guidelines.
Study protocol
In all women, weight, height, WC and hip circumference (HC) were measured. Body weight was measured with an analog scale and in light clothing; height was measured barefoot with a stadiometer. BMI (kg/m 2 ) was calculated in order to assess obesity. The WC was recorded as the smallest circumference at the level of the umbilicus and the HC was measured at the widest point around the buttocks. The waist:hip ratio (WHR) was calculated by dividing WC by HC. SBP and DBP were measured with an automatic sphygmomanometer and the mean of three measurements was recorded.
Blood samples for baseline measures were collected after an overnight fast between Days 3 and 7 of the menstrual cycle in the control group and after a spontaneous bleeding episode in the PCOS group. The circulating levels of FSH, LH, prolactin, total testosterone, D 4 -androstenedione (D 4 -A), dehydroepiandrosterone-sulfate (DHEA-S), 17a-OHP, sex hormonebinding globulin (SHBG), glucose, insulin, total cholesterol (TC), HDL-C and TG were measured. Low-density lipoprotein cholesterol levels were calculated using Friedewald's formula (Friedewald et al., 1972) . Immediately after baseline blood sampling, an oral glucose tolerance test (OGTT) was performed; 75 g of glucose was administered orally and serum glucose levels were determined after 30, 60, 90 and 120 min. On the same day, transvaginal ultrasonography was performed and the volume of each ovary was determined, as well as the number of small follicles (measuring 2 -9 mm in diameter) in each ovary.
Hormones and markers of IR
Serum FSH, LH, prolactin, androgen, 17a-OHP, SHBG, glucose, insulin, TC, HDL-C and TG concentrations were measured as previously described (Macut et al., 2006; Piouka et al., 2009) . Free androgen index (FAI) was determined as follows: FAI ¼ total testosterone (nmol/l) × 100/SHBG (nmol/l) (Carter et al., 1983) . The homeostasis model assessment of IR (HOMA-IR) index was calculated as follows: HOMA-IR ¼ fasting insulin (mIU/ml) × fasting glucose (mg/dl)/405 (Matthews et al., 1985) . The quantitative insulin sensitivity check index (QUICKI) was calculated according to the following formula: QUICKI ¼ 1/[logInsulin (mIU/ ml) + logGlucose (mg/dl)] (Katz et al., 2000) .
Transvaginal ultrasonography
Transvaginal ultrasound scans of the ovaries were performed by an experienced sonographer in women who participated in the study. Ovarian volume was calculated by the formula: 
Statistical analysis
Data analysis was performed with the statistical package SPSS (version 17.0; SPSS Inc., Chicago, IL, USA). Data are reported as mean + SD. Differences in continuous variables between the groups were assessed with one-way analysis of variance with the Holm -Sidak method for multiple comparison testing. Comparisons between the groups were also performed with analysis of covariance adjusting for age and BMI. In all cases, a P-value of ,0.05 was considered significant.
Results
Anthropometric characteristics of women with PCOS and controls according to the presence of MetS are shown in Table I . Women with PCOS were younger than controls, whereas age did not differ between women with MetS and those without MetS in either women with PCOS or in controls. In both women with PCOS and in controls, patients with MetS had greater BMI, WC and WHR than those without MetS. In addition, controls with MetS had greater BMI, WC and WHR than those with PCOS but without MetS. Moreover, controls with MetS had higher SBP, DBP and serum TG levels, and lower HDL-C levels than women with PCOS but without MetS. In contrast, SBP, DBP, WC and serum HDL-C and TG levels did not differ between women with both PCOS and MetS and those without PCOS but with MetS: similarly, these parameters did not differ between women with PCOS but without Mets and those without either PCOS or MetS.
Markers of IR in women with PCOS and controls according to the presence of MetS are shown in Table II . In both women with PCOS and in controls, women with MetS were more insulin-resistant [i.e. they had higher serum insulin levels, area under the OGTT curve (AUC OGTT) and HOMA-IR and lower glucose/insulin ratio and QUICKI] than those without MetS. In contrast, women with both PCOS and MetS showed only borderline significant differences in some markers of IR (glucose/insulin ratio and QUICKI) compared with those without PCOS but with MetS (i.e. the former had lower glucose/insulin ratio and QUICKI; P , 0.05 for both comparisons).
Similarly, women with PCOS but without MetS showed only borderline significant differences in some markers of IR (AUC OGTT) compared with those without either PCOS or MetS (i.e. the former had higher AUC OGTT; P , 0.05). Moreover, women without PCOS but with MetS were more insulin-resistant (i.e. they had higher serum insulin levels, AUC OGTT and HOMA-IR and lower QUICKI) than those with PCOS but without MetS (P , 0.001 for all comparisons).
Endocrine characteristics of women with PCOS and controls according to the presence of MetS are shown in Table III . In both women with and without MetS, women with PCOS had higher levels of circulating androgens (total tesosterone, D 4 -A, DHEA-S and FAI) than controls. In women with PCOS, the FAI was higher in women with MetS than in those without, whereas the levels of other androgens did not differ between the two groups. In controls, none of the measured androgens differed between women with and without MetS.
Similar findings were observed when comparisons between the groups were performed after adjustment for age and BMI (Tables I -III) . Similar findings were also observed when PCOS was defined according to the AES criteria (Table IV) . Similar findings were also observed when MetS was defined according to the criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III, by the AHA/NHLBI and by the IDF (data not shown) (Adult Treatment Panel III, 2002; Alberti et al., 2005; Grundy et al., 2005) .
Discussion
Even though PCOS and MetS apparently share many similar characteristics, primarily abdominal obesity and IR, to the best of our knowledge, this is the first study that compared markers of IR in women with PCOS versus women with MetS. We show that women with MetS are more insulin-resistant than those with PCOS, even after adjusting for the greater BMI in the former. Previous studies focused only on the comparison of markers of IR between women with both PCOS and MetS versus those with PCOS but without MetS, and reported that the former are more insulin-resistant than the latter (Dokras et al., 2005; Ehrmann et al., 2006; Attaoua et al., 2008; Cussons et al., 2008) . However, in most studies, women with both PCOS and MetS were more obese than those who only had PCOS and adjustment for this difference was not performed (Dokras et al., 2005; Ehrmann et al., 2006; Cussons et al., 2008; Hosseinpanah et al., 2011) . In the present study, women with both PCOS and MetS were also more insulin-resistant than those with only PCOS and this difference persisted after adjusting for the greater BMI in the former. In addition, women with only MetS were more insulin- Non-significant differences after adjusting for age and BMI. *One-way analysis of variance. NS, not significant; NA, not applicable; PCOS, polycystic ovary syndrome; MetS, metabolic syndrome; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.
resistant than healthy women, independently of the difference in BMI. In contrast, women with only PCOS showed only borderline differences in markers of IR compared with BMI-matched healthy women. Overall, these findings suggest that IR is primarily driven by obesity in PCOS and is less pronounced in these women than in women with MetS. An interesting finding in our study was that women with PCOS showed only marginal differences in markers of IR compared with BMI-matched women without PCOS. This contravenes previous reports showing that women with PCOS are more insulin-resistant than BMI-matched controls and that IR is present in women with PCOS regardless of BMI (Dunaif et al., 1989) . This discrepancy might be partly due to the methods used to assess IR, because we used the HOMA-IR, QUICKI and OGTT, which are not as sensitive as the euglycemic hyperinsulinemic clamp that was used in the former studies (Cagnacci et al., 2001; Diamanti-Kandarakis et al., 2004) . Nevertheless, it should be emphasized that women with PCOS in our study did show differences in certain markers of IR (glucose/insulin ratio, QUICKI and AUC OGTT) compared with those without PCOS, i.e. had lower glucose/insulin ratio and QUICKI, and higher AUC OGTT, than the latter. However, these differences were marginally significant and serum insulin levels and the HOMA-IR did not differ between women with PCOS and those without PCOS. Therefore, women with PCOS appear to be more insulin-resistant than those without PCOS, but IR in this syndrome does not appear to be as severe as in MetS and requires sensitive or multiple methods to be accurately identified.
We also show that women with both PCOS and MetS have higher FAI than those who have only PCOS. This increase in circulating androgens in MetS is in agreement with previous reports in women with PCOS (Apridonidze et al., 2005; Cussons et al., 2008; Cheang et al., 2009) and with a recent meta-analysis of studies both in women with PCOS and in the general population (Brand et al., 2011) . It is possible that abdominal obesity, a defining characteristic of MetS, is associated with this increase in circulating free androgens, since adipose tissue can synthesize and secrete active androgens (Corbould et al., 2002; Quinkler et al., 2004) . In our study, circulating androgens did not differ between women with MetS and those without MetS in the absence of PCOS. It is possible that this is due to the relatively small size of this subgroup (n ¼ 277) and the variability of androgen levels. On the other hand, MetS might not have a substantial effect on circulating androgens. Indeed, only FAI was higher in patients with MetS in our study, whereas the levels of other androgens were comparable between women with and without MetS. In addition, previous studies in women with PCOS that reported higher androgen concentration in women with MetS did not adjust for the greater BMI in the former (Cussons et al., 2008; Cheang et al., 2009) . Moreover, other studies in PCOS did not show any difference in circulating androgens between women with both PCOS and MetS and those with PCOS but without MetS, even though the former were more obese than the latter (Dokras et al., 2005; Ehrmann et al., 2006; Hosseinpanah et al., 2011) . Overall, the association of MetS and hyperandrogenemia requires further investigation in both women with PCOS and in the general population.
Hyperandrogenism is a pivotal characteristic of PCOS and it has been argued that it represents a sine qua non for the diagnosis of this syndrome. Accordingly, we performed additional analyses applying Non-significant differences after adjusting for age and BMI.
the AES criteria for the diagnosis of PCOS, but the results were almost identical with our findings when we used the less stringent revised Rotterdam criteria, i.e. women with PCOS were not substantially more insulin-resistant than those without PCOS even when hyperandrogenism was required for the diagnosis of PCOS. These findings are somewhat unexpected, because hyperandrogenism appears to be implicated in the pathogenesis of IR in women with PCOS. Indeed, in vitro data suggest that testosterone induces IR through a postreceptor mechanism (Corbould, 2007) and exogenous administration of testosterone induces IR in humans (Polderman et al., 1994) . In addition, removal of ovarian hyperandrogenism by GnRH analogs improves insulin sensitivity in women with PCOS (Dahlgren et al., 1998; Cagnacci et al., 1999) . As already mentioned, it is possible that the methods that we used to evaluate IR in our study were not sufficiently sensitive to detect subtle differences in insulin sensitivity between hyperandrogenemic women with PCOS and women without PCOS (Diamanti-Kandarakis et al., 2004) . On the other hand, there were differences in certain markers of IR between these two groups, suggesting more severe IR in hyperandrogenemic women with PCOS, but these differences were marginally significant. However, our study was not designed to assess the contribution of hyperandrogenism to the pathogenesis of IR in PCOS and specifically designed studies are required to clarify this association. Our findings potentially have important implications. First, it is well established that MetS is associated with increased risk for type 2 diabetes mellitus (T2DM) (Ford et al., 2008) , but whether this association is also present in PCOS is unclear (Legro et al., 2005; Boudreaux et al., 2006) . Our finding that IR is significantly less pronounced in PCOS than in MetS also supports a weaker link between PCOS and T2DM than between MetS and T2DM. Second, patients with MetS have an almost 2-fold higher risk for cardiovascular events (Mottillo et al., 2010) , whereas the data are inconclusive regarding an association between PCOS and cardiovascular mortality (Pierpoint et al., 1998; Wild et al., 2000; Shaw et al., 2008) . In addition to the less severe IR in PCOS than in MetS, women with PCOS in the present study did not differ in other major cardiovascular risk factors (blood pressure, serum HDL-C and TG levels) versus BMI-matched controls. This finding suggests that PCOS might be a weaker cardiovascular risk factor than MetS.
In conclusion, women with PCOS but without MetS have less severe IR than those without PCOS but with MetS. On the other hand, circulating androgens do not appear to be considerably elevated in women with MetS. Therefore, PCOS should not be considered as a manifestation of MetS and vice versa, despite the similarities of these entities. It remains to be established whether the less pronounced IR in women with PCOS translates into lower long-term risk for T2DM than in women with MetS.
